Peripheral plasmablasts in anti-MuSK myasthenia gravis

Guillermo Delgado-García, Teresa Corona-Vázquez

Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City 14269, Mexico.

Correspondence to: Prof. Teresa Corona-Vázquez, Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Insurgentes Sur #3877, Col. La Fama, Del. Tlalpan, Mexico City 14269, Mexico. E-mail: coronav@unam.mx

How to cite this article: Delgado-García G, Corona-Vázquez T. Peripheral plasmablasts in anti-MuSK myasthenia gravis. Neuroimmunol Neuroinflammation 2017;4:236-7.

As Hong and Sung[1] previously did, we read with great interest the study published by Guptill et al.[2] They reported that anti-muscle-specific kinase (MuSK) myasthenia gravis patients and healthy controls had similar percentages of peripheral plasmablasts. This result is derived from a comparison between 13 female patients (out of the 18 originally included in the study) and 6 controls[2]. Taking into account the effect of rituximab on peripheral plasmablasts[3], those patients treated with it (n = 3) were not included in the previous comparison. Excluding these patients, 6 (40%) were on chronic prednisone treatment, whose dose was between 2.5 mg every other day and 20 mg daily. However, it is already known that prednisone therapy effectively decreases peripheral plasmablasts[4], so this could contribute to the lack of difference between patients and controls. They also reported that immunosuppressed (n = 7) and non-immunosuppressed (n = 6) patients had similar percentages of peripheral plasmablasts. A comparison between non-immunosuppressed patients and controls would have also been quite informative, since it would eliminate the prednisone factor and facilitate the demonstration of a difference between a seemingly normal population of peripheral plasmablasts (controls) and an abnormal one (patients). Finally, vaccination history in controls is also an important point to consider, since it has been documented that peripheral plasmablasts increase after vaccination[5].

Increased peripheral plasmablasts have been found in various immune-based diseases. IgG4-related disease is one of these conditions[6]. In connection with the above, Raibagkar et al.[7] recently reported the case of a 54-year-old woman with anti-MuSK myasthenia gravis who also developed retroperitoneal lymphadenopathy histopathologically consistent with IgG4-related disease. They did not report the count of peripheral plasmablasts in this patient. We conducted a search in PubMed and found an additional case of a 72-year-old man with myasthenia gravis who also developed an inflammatory aortic aneurysm. The latter was compatible with a possible diagnosis of IgG4-related disease. Nevertheless, the antibody involved in the diagnosis of myasthenia gravis in this patient is not reported[8].

In the title of their short communication, Raibagkar et al.[7] wonder if there is any relationship between the two diseases. It is interesting to note that in anti-MuSK
myasthenia gravis antibodies are directly pathogenic\textsuperscript{[9]}, whereas in IgG4-related disease they are probably not\textsuperscript{[7,10]}. We recently stressed that the sphere of IgG4-mediated neurological autoimmune disorders is an expanding one\textsuperscript{[10]}. We believe that the study of the ties between IgG4-mediated neurological autoimmune disorders and IgG4-related disease could represent a very fruitful field in the near future\textsuperscript{[10]}, so further studies are needed in this specific area. However, one of the limitations that these studies might face is the low prevalence (or underdiagnosis) of these conditions\textsuperscript{[11,12]}\textsuperscript{[10]}. Multicentric studies through international, collaborative efforts could mitigate this limitation. Regarding the technical aspects, it is also necessary to unify the characterization (gating) of peripheral plasmablasts in order to facilitate dialogue and exchange between different research communities, which may come from different domains of specialization (neurology, rheumatology, immunology, among others).

DECLARATIONS

Authors’ contributions
Literature review, significant contribution to intellectual manuscript content, and manuscript drafting: G. Delgado-García, T. Corona-Vázquez.

Financial support and sponsorship
None.

Conflicts of interest
There are no conflicts of interest.

Patient consent
Not applicable.

Ethics approval
Not applicable.

REFERENCES


